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OBJECTIVE: Women with chronic kidney disease (CKD) are
often at risk of experiencing polypharmacy. Polypharmacy is
deﬁned as the excessive use of drugs. This study examined varia-
tions in numbers of medications used by women with CKD in
outpatient settings in the United States. METHODS: This cross-
sectional study used data from the National Ambulatory Medical
Care Survey (NAMCS) from 1996–2003. Women aged 18 years
and older with CKD were included in the study sample based on
clinical diagnoses and the reason for the visit. Polypharmacy was
determined by retrieving number of medications used (5 medi-
cations) during the time of visit (retrieved using the NAMCS
drug codes). All analyses were weighted to make national
estimates. RESULTS: There were approximately 58 million
weighted outpatient visits for women with CKD from 1996 to
2003. The mean age for this population is 62. Nearly 14% of
these visits were by Hispanic women. Nephrologists accounted
for only 15% of CKD patient visits. Just over 4% of women
reported having 8 medications at the time of their visits. Further-
more, 32% of patients were using 5 medications. Multivariate
analysis showed that women seen by nephrologists were about
two times more likely (OR:1.9;95% CI: (1.19–3.30) (p  0.05)
to receive a prescription for 5 medications than those not
seeing a nephrologist. Hispanic women were 54% less likely
(OR:0.46;95% CI: (0.23–0.94) (p  0.05) to receive a prescrip-
tion for 5 medications than non Hispanic patients. Addition-
ally, this study also identiﬁed signiﬁcant regional and time
variations (p  0.05) in polypharmacy trends within this popu-
lation in U. S. outpatient settings. CONCLUSION: The ﬁndings
of this study suggest that polypharmacy is prevalent in this
population within U.S. outpatient settings. Increased awareness
among clinicians is needed regarding the impact of polyphar-
macy on women with CKD in outpatient settings in the U.S.
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OBJECTIVE: Use of home dialysis (HomD) therapies, home
hemodialysis and peritoneal dialysis (PD), comprise approxi-
mately 8% of total dialysis utilization in the United States. The
remainder being hemodialysis (HD) performed in-center. Recent
work suggests 50%ormore dialysis patients could receiveHomD.
The objective of this study is to evaluate whether dialysis facility
characteristics affect HomD use. METHODS: The number of
facility point prevalent (December 31, 2006) dialysis patients on
HomDand facilityHDwas extracted from end-stage renal disease
(ESRD) network annual reports. Data on ownership status (proﬁt/
not-for-proﬁt), chain status (independent or managed/owned by a
chain organization), night shift for dialysis, and the number ofHD
stationswere obtained fromMedicare’s Dialysis Facility Compare
(DFC) database. A regression model was used to estimate the
impact of these factors on utilization of HomD (e.g., percent of
total dialysis patients on HomD). Additional risk adjusters
included a rural/urban indicator, percent of dialysis patients
employed, and percent of dialysis population 18 to 54 years of age.
RESULTS: There were 3480 facilities in the analysis. As the
number of HD patients per HD station increases the percent of
patients on HomD signiﬁcantly decreases at an increasing rate. If
the facility has a late shift, the percent of patients on HomD is 6
percent higher than in facilities without a late shift (p < 0.001). If
a facility is for-proﬁt, a chain organization, or is located in a more
rural area, the percent of patients on HomD signiﬁcantly
decreases. Finally, a facility with the median of 62 or more dialysis
patients has a signiﬁcantly greater use ofHomD.CONCLUSION:
HomD was more common in not-for-proﬁt and independently
managed/owned facilities. The ﬁnancial implications of these
ﬁndings may be signiﬁcant as in-center HD is 37% more costly
than a home option in the Medicare population.
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Organization: Unimed Vitoria health insurance Company. Work
Medicine Cooperative.
Problem or Issue Addressed: Increased costs and utilization of
GCSF for the treatment of oncology patients within Unimed
Vitoria, without any change in the ASCO indication criteria and
cancer incidence.
Goals: 20% cost reduction of GCSF treatment of oncology
patients through strict compliance of ASCO guidelines.
Outcomes items used in the decision: Cost-effective study on
GCSF indication in different tumors and actual clinical applica-
tion (interest conﬂicting prescription medicine).
Implementation Strategy: Single-observer evaluation of all GCSF
requests and consequent release by the health insurance company
only if the indication met ASCO guideline.
Results: Signiﬁcant GCSF cost and utilization reduction from
December 2005 to December 2007. The utilization reduction in
2006 was 25% followed by another 10% in 2007. The cost
reduction was even greater as a result of direct purchase of the
drug by the health insurance company.
Lessons Learned: Direct purchase of medications by the health
care professional that is responsible for the prescription and drug
distribution may increase drug prescription without scientiﬁc
support.
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Organization: The Health Economics Unit of the University of
the West Indies conducted an investigation into diffusion of
laparoscopic general surgery in Trinidad and Tobago.
Problem or Issue Addressed: The adoption of new health tech-
nologies increasingly requires evidence of effectiveness (and cost-
effectiveness). However, even where such evidence is available, its
inﬂuence in modifying clinician behaviour is variable. Where
current clinical practice resists the adoption of new technologies
with demonstrable cost-effectiveness, then this is likely to lead to
a) sub-optimal health outcomes for patients, and (b) inefﬁcient
and wasteful use of scarce health care resources. Minimally inva-
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sive surgical techniques have been available for over 20 years. By
the late 1990’s laparoscopy was seen internationally as the future
of general surgery. The ﬁrst laparoscopic cholecystecomy (LC) in
Trinidad had been performed in 1991. However, by 2003 this
procedure was still not being performed at public hospitals in
Trinidad and Tobago. Even in private hospitals only 7% of
cholecystectomies were being performed laparoscopically. This
was seen as a problem because LC is recognized as the ‘ﬁrst step’
towards more widespread use of laparoscopic procedures in
general surgery. A failure of the health system to adopt LC would
translate to a failure to develop general laparoscopic surgery.
Further, the population was being denied the well-documented
patient beneﬁts of LC in terms of reduced pain and shorter
recovery time.
Goals: The objective of the study was to gain an understanding of
the reasons for the failure to adopt laparoscopic cholecystectomy
more widely despite the presence of surgeons who were able to
perform the procedure and the availability of the required equip-
ment in private hospitals. Recommendations for action were to
be made based on these ﬁndings.
Outcomes items used in the decision: Surgeon and Administrator
opinions on the clinical and cost-effectiveness of LC compared to
Open Cholecystectomy (OC) and Minilap Cholecystectomy
(MC). A cost-effectiveness analysis was carried out comparing
these three procedures. Implementation Strategy: The views of
consultant surgeons about the clinical and economic impact of
LC versus other approaches, and their reasons for not perform-
ing were obtained by interview. Administrators in the Regional
Health Authorities were also interviewed to obtain information
about why LC had not been adopted in their hospitals. A meta-
analysis based cost-effectiveness analysis was conducted that
compared costs and beneﬁts measured at (a) the level of the
individual hospital and (b) the societal level for three procedures:
OC, MC and LC for public hospitals in Trinidad and Tobago.
Results: Investigations revealed widespread belief among sur-
geons and administrators that LC substantially increased cost to
the health care system. Over 60% of surgeons believed that MC
was the lowest cost approach. The cost-effectiveness analysis
showed that for Trinidad and Tobago, an LC programme would
result in substantial savings over OC and MC programmes both
at hospital level for society. Results of the cost-effectiveness
analysis along with the clinical potential of a laparoscopic
surgery programme (for example the potential for other mini-
mally invasive procedures that could be adopted) were presented
to physicians, administrators and policy makers in 2003–4. The
presentations were well received. Several hospitals were perform-
ing LC by 2005, and by 2007 all of the major hospitals had
acquired the necessary equipment and were performing LC. Post-
implementation data shows that LC is being performed well
within the limits of the key cost drivers in the CEA model, so that
cost savings are at least at predicted level.
Lessons Learned: Policy makers and clinicians responded to a
locally conducted cost-effectiveness analysis (albeit one using
published data from overseas). The diffusion-failure of LC
appeared largely to result from a failure to access relevant infor-
mation on cost-effectiveness and this represented a misallocation
of resources. The project pointed to the potential role for eco-
nomic evaluation methods in health resource allocation decision-
making in Trinidad and Tobago. A general framework for the
prioritization of health interventions is currently being developed
for Trinidad and Tobago. The aim is to develop a single frame-
work which can be used to inform resource allocation decisions
at various levels and which can be easily deployed in other
Caribbean islands. A review of criteria to guide explicit prioriti-
zation concluded with a recommendation that EuroQol EQ-5D
be used to obtain local values for health states which can in turn
be used to quantify the beneﬁts of health care interventions for
economic evaluations.
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Center (UT-MDACC) Department of Drug Use Policy and Phar-
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Problem or Issue Addressed: Pharmacy budgets for cancer treat-
ment are ever increasing and are contributed to by the addition of
targeted therapies to standard cancer treatment regimens. As part
of our formulary management process, we conducted and pre-
sented an pre formulary admission and post admission economic
analysis of bortezomib in combination with standard chemo-
therapy for refractory or relapsed multiple myeloma.
Goals: The purpose of this project was to incorporate budget
impact and cost-effectiveness considerations into the Pharmacy
and Therapeutics Committee’s deliberations about the approval
for addition of a new product to the standard of care chemo-
therapy in the institution. A pre-approval economic model for
bortezomib was built, which included annual budget impact and
cost-effectiveness, and was presented to the Pharmacy and Thera-
peutics Committee in 2003. In 2007, a post-approval economic
analysis was presented again to the Pharmacy and Therapeutics
Committee in order to assess the actual annual budget impact of
bortezomib and compare it to the pre-approval economic model.
Outcomes items used in the decision: The institutional annual
budget impact analysis was done using direct medical costs,
in 2007 United States Dollars. A cost per life year saved was
also calculated for the initial Pharmacy and Therapeutics
consideration.
Implementation Strategy: A model was built based on the
indication of treatment of relapsed and refractory multiple
myeloma as third line treatment. Assumptions regarding bort-
ezomib’s number of doses per cycle, per patient and median
number of cycles per patient were based on information from
published clinical trials. Annual budget impact for the expected
MD Anderson population of 25 multiple myeloma patients,
adjusted for 2007, was calculated to be $414,974 and a cost
per life year saved was calculated as $14,592. This model,
along with a clinical monograph, was presented to the P&T
Committee at the same time as the vote for bortezomib’s inclu-
sion onto formulary. Subsequently, bortezomib was added to
the formulary as an add-on drug for refractory or relapsed mul-
tiple myeloma patients with two prior therapies, and with the
recommendation that physicians use discretion for use outside
the FDA-indication.
Results: We reviewed non-investigational usage of bortezomib in
MDACC from June 2006 to May 2007, after allowing ample
time since its addition to the formulary to penetrate the institu-
tion. We had a total of 161 patients on bortezomib. Of these, 140
(87%) were refractory or relapsed multiple myeloma patients
who had prior therapies, 7 (4%) were mantle cell lymphoma
patients with prior treatments, and 14 (9%) patients received
bortezomib for non FDA-approved indications. Refractory or
relapsed multiple myeloma was FDA-approved in March, 2005
for second line therapy, whereas mantle cell lymphoma was
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